Top Markets
Coin of the day
PaxMedica, Inc. Common Stock PaxMedica, Inc. Common Stock

PaxMedica, Inc. Common Stock

PXMD
주식 순위 #40911
PaxMedica, Inc. is a biopharmaceutical company currently in the clinical... PaxMedica, Inc. is a biopharmaceutical company currently in the clinical development phase, dedicated to advancing anti-purinergic drug therapies (APTs). These innovative treatments are specifically designed to address complex neurological disorders presenting with stubborn and persistent symptoms. The company's primary investigative drug is PAX-101, an intravenous (IV) form of suramin, which is being explored for a variety of conditions. These include autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, post-COVID-19 syndrome (commonly known as "long COVID"), and human African trypanosomiasis. Furthermore, PaxMedica is also developing PAX-102, an intranasal version of suramin, intended for various neurological applications. The company, which was incorporated in 2018 and has its headquarters in Tarrytown, New York, previously operated as Purinix Pharmaceuticals LLC before rebranding to PaxMedica, Inc. in April 2020. It functions as a subsidiary of Tardimed Sciences LLC.
주가
$0.0005
마지막 동기화: 2026-08-12
시가총액
$63.13K
변동 (1일)
0.00%
변동 (1년)
150.00%
국가
US
거래 PaxMedica, Inc. Common Stock (PXMD)

카테고리

PaxMedica, Inc. Common Stock (PXMD)의 매출
Aug 2026 기준 매출 TTM: 0
PaxMedica, Inc. Common Stock의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
PaxMedica, Inc. Common Stock의 수익 기록 (2026 ~ 2026)
매년 말 매출
연도 매출 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
$12.62B -
US
$6.02B -
NL
- -
CH
- -
KR
$10.11B -
BE